GW is the global leader in developing cannabinoid-based medicines. Cannabidiol (approved by FDA as Epidiolex® in the United States) is in development to treat certain rare and catastrophic forms of childhood-onset epilepsy that currently have few treatment options.

Healthcare Professionals: Learn more about cannabidiol (CBD) development

GW’s vision is to be the global leader in prescription cannabinoid medicines, developing and commercializing pharmaceutical products which address clear unmet needs.
Justin Gover, Chief Executive Officer
GW's vision pic


Nov 27, 2018
- Epidiolex ® (cannabidiol) oral solution (CV), first FDA -approved plant-derived cannabinoid medicine launched in the U.S. - - Conference call today at 4:30 p.m. EST - LONDON and CARLSBAD, Calif. , Nov. 27, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the
Nov 26, 2018
- Primary endpoint achieved with both EPIDIOLEX doses compared to placebo -  - Today’s data represents the fourth positive Phase 3 pivotal trial for EPIDIOLEX in Dravet syndrome and Lennox-Gastaut Syndrome - - EPIDIOLEX recently launched in the US and is now available by prescription -   LONDON,
Nov 19, 2018
Meeting Highlights Include over 20 Posters and Virtual Tour of the Epidiolex Manufacturing Process LONDON and CARLSBAD, Calif., Nov. 19, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), the world leader in the development and commercialization of